# Ozurdex for Combined Pseudophakic Cystoid Macular Edema and Diabetic Macular Edema After Cataract Surgery

> **NCT01284478** · PHASE2 · COMPLETED · sponsor: **Northern California Retina Vitreous Associates** · enrollment: 6 (actual)

## Conditions studied

- Pseudophakic Cystoid Macular Edema,
- Diabetic Macular Edema

## Interventions

- **DRUG:** Dexamethasone Implant

## Key facts

- **NCT ID:** NCT01284478
- **Lead sponsor:** Northern California Retina Vitreous Associates
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2012-10-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01284478

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01284478, "Ozurdex for Combined Pseudophakic Cystoid Macular Edema and Diabetic Macular Edema After Cataract Surgery". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01284478. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*